SOURCES:
William Schaffner, MD, professor of preventive drugs and infectious illness specialist, Vanderbilt College Medical Middle, Nashville; medical director, Nationwide Basis for Infectious Ailments.
Ann Falsey, MD, professor of drugs and respiratory viruses researcher, College of Rochester Faculty of Medication, Rochester, NY.
Aaron Glatt, MD, chair, Division of Medication; chief of infectious ailments and hospital epidemiologist, Mount Sinai South Nassau; professor of drugs, Icahn Faculty of Medication at Mount Sinai, Oceanside, NY.
Leonard Friedland, MD, vice chairman and director, scientific affairs and public well being, vaccines, GSK.
Pfizer spokesperson.
FDA: “FDA approves first respiratory syncytial virus (RSV) vaccine,” “FDA Roundup June 2.”
World Well being Group: “Respiratory Syncytial Virus (RSV) illness.”
CDC: “RSV Surveillance & Analysis,” “RSV Transmission,” “RSV Signs and Care.”
GSK: “US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults.”
Pfizer: “U.S. FDA Approves ABRYSVO, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults.”
The New England Journal of Medication: “Efficacy and Security of a bivalent RSV Prefusion F Vaccine in Older Adults,”“Bivalent Prefusion F Vaccine in Being pregnant to Stop RSV Sickness in Infants,”“Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.”
AstraZeneca: “Nirsevimab unanimously beneficial by FDA Advisory Committee for the prevention of RSV decrease respiratory tract illness in infants.”